Gabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial From the Gabapentin Cancer Pain Study Group

Caraceni, Augusto; Zecca, Ernesto; Bonezzi, C.; Arcuri, Edoardo; Yaya-Tur, Ricardo; Maltoni, Marco; Visentin, Marco; Gorni, Giovanna; Martini, Cinzia; Tirelli, Walter; Barbieri, Massimo; Conno, F. De

doi:10.1200/jco.2004.08.141

Cited by 273 publications

(191 citation statements)

References 36 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…It is believed that gabapentin acts on the α-2-δ type of Ca 2+ channels. Gabapentin has relieved pain and associated symptoms in patients with both peripheral diabetic neuropathy, post-herpetic neuralgia, HIV-related neuropathy, and cancer-related neuropathic pain [41]- [44]. The dosages used in these studies typically ranged from 900 -3600 mg daily in 3 divided doses.…”

Section: Gabapentinmentioning

confidence: 99%

The Use of Antiepileptic Drugs in Acute Neuropsychiatric Conditions: Focus on Traumatic Brain Injury, Pain, and Alcohol Withdrawal

Nejad

Chuang²,

Hirschberg³

et al. 2014

IJCM

View full text Add to dashboard Cite

Antiepileptic drugs (AEDs), have demonstrated efficacy treating a number of acute conditions, encompassing a broad range of symptoms and syndromes, in addition to being first-line treatment for epilepsy. Clinically, since their inception, AEDs have been used off-label for acute and chronic medical conditions, both as primary and as adjuvant therapies. In this review, we describe the observed clinical effectiveness of AEDs across a set of commonly encountered acute conditions in the general hospital: traumatic brain injury, pain, alcohol withdrawal. In describing the individual benefits and usages of specific agents, the applicability of these agents to other common neuropsychiatric conditions may be further explored.

show abstract

Section: Gabapentinmentioning

confidence: 99%

The Use of Antiepileptic Drugs in Acute Neuropsychiatric Conditions: Focus on Traumatic Brain Injury, Pain, and Alcohol Withdrawal

Nejad

Chuang²,

Hirschberg³

et al. 2014

IJCM

View full text Add to dashboard Cite

show abstract

“…An inconvenience with the use of opioids is that this type of drug may be overused, abused or misused in chronic cancer [50]. An anticonvulsant, gabapentin, has been demonstrated to be useful in the treatment of neuropathic cancer pain [51], as well as having adjuvant properties, synergistic with opioid analgesics [52].…”

Section: Other Treatments Of Sres In Patients With Advanced Cancermentioning

confidence: 99%

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

Rolfo¹,

Raez²,

Russo³

et al. 2013

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

INTRODUCTION:\ud The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting.\ud AREAS COVERED:\ud Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the prevention of cancer-related events in skeleton. This paper reviews several trials evaluating the efficacy of denosumab in comparison with zoledronic acid in patients with solid osteotropic tumors. In this setting of skeleton-invading cancers, denosumab was demonstrated to be superior to zoledronic acid in preventing or delaying SREs. In comparison with zoledronic acid, denosumab significantly delayed the time to first SRE by 17%.\ud EXPERT OPINION:\ud Current research on denosumab is addressed to prove the immunomodulator effect of this agent in humans. Other avenue of research is focused on its antitumor activity observed in some Phase III trials

show abstract

“…As opposed to non-cancer pain states, few studies have evaluated gabapentin for the treatment of cancer-related pain. These studies showed significant differences in pain intensities, although the clinical meaning remains uncertain [4,34]. There have been no head-to-head studies to directly compare the efficacies of gabapentin and pregabalin.…”

Section: Non-opioid Drugsmentioning

confidence: 99%

Emerging drugs for cancer-related pain

Mercadante

2011

Support Care Cancer

View full text Add to dashboard Cite

Gabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial From the Gabapentin Cancer Pain Study Group

Abstract: Gabapentin is effective in improving analgesia in patients with neuropathic cancer pain already treated with opioids.

Cited by 273 publications

References 36 publications

The Use of Antiepileptic Drugs in Acute Neuropsychiatric Conditions: Focus on Traumatic Brain Injury, Pain, and Alcohol Withdrawal

The Use of Antiepileptic Drugs in Acute Neuropsychiatric Conditions: Focus on Traumatic Brain Injury, Pain, and Alcohol Withdrawal

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

Emerging drugs for cancer-related pain

Contact Info

Product

Resources

About